Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer
This trial is active, not recruiting.
|Condition||non-small cell lung cancer|
|Sponsor||The First Affiliated Hospital of Guangzhou Medical University|
|Start date||February 1996|
|End date||January 2010|
|Trial size||100 participants|
|Trial identifier||NCT00997724, FAHG96016|
The purpose of this study is to examine the feasibility of assisted-VATS (video-assisted thoracoscopic surgery) sleeve lobectomy for non-small cell lung cancer for non-small cell lung cancer. Success is defined as assisted-VATS sleeve lobectomy without conversion. If success rate over 90%, assisted-VATS sleeve lobectomy is considered as feasible procedures for non-small cell lung cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
If success rate over 90%, assisted-VATS sleeve lobectomy is considered as feasible procedures for non-small cell lung cancer. (Success is defined as assisted-VATS sleeve lobectomy without conversion).
time frame: 3 months
To evaluate the intraoperative(surgical duration, estimated blood loss), postoperative variables(mortality, morbidity, chest tube drainage duration, hospital stay), and 5-year survival rates.
time frame: 3 months
Male or female participants from 18 years up to 80 years old.
Inclusion Criteria: - Histologically confirmed non-small cell lung cancer (Squamous, adenosquamous, large cell, or poorly differentiated) - Patients with central tumors located at the origin of a lobar bronchus. - ECOG performance status 0-1 - Hematopoietic: WBC at least 4,000/mm^3; Platelet count at least 100,000/mm^3 - Hepatic: Bilirubin normal; AST/ALT no greater than 1.5 times upper limit of normal (ULN); Alkaline phosphatase no greater than 2.5 times ULN - Renal: Creatinine clearance greater than 60 ml/min - Cardiovascular: Cardiac function normal Exclusion Criteria: - Severe complications or infections - Pregnant or breast-feeding women - Clinically significant heart disease - Uncontrolled hepatitis, chronic liver disease, or diabetes mellitus - Another active cancer except properly treated carcinoma in situ of the cervix or basal/squamous cell skin carcinoma
|Official title||Feasibility of Assisted-VATS(Video-Assisted Thoracoscopic Surgery) Sleeve Lobectomy for Non-small Cell Lung Cancer|
|Description||Sleeve lobectomy is removal of a portion of a main stem bronchus in continuity with the adjacent lobe or bilobe followed by end-to-end bronchial anastomosis. The first reported bronchial sleeve resection was performed in 1947 at the Brompton Hospital in London, England, by Sir Clement Price Thomas. Whether sleeve resection is radical enough and indicated for patients who could tolerate pneumonectomy continues to be debated, although many recent reports have suggested that sleeve resection can achieve adequate curability rates. However, sleeve lobectomy has a definite role in the surgical management of lung cancer for patients whose pulmonary reserve is considered inadequate to permit pneumonectomy, and should be used anytime it is possible to achieve a margin-negative (R0) resection. Although video-assisted thoracic surgery (VATS) is regarded as a minimally invasive procedure with good long-term survival results, many surgeons think that VATS is too complex and has too many technical limitations to be applied to bronchoplasty. Therefore, there are few reports in the literature of VATS bronchoplasty for lung cancer. The purpose of this study is to examine the feasibility of assisted-VATS (video-assisted thoracoscopic surgery) sleeve lobectomy for non-small cell lung cancer for non-small cell lung cancer. Success is defined as assisted-VATS sleeve lobectomy without conversion. If success rate over 90%, assisted-VATS sleeve lobectomy is considered as feasible procedures for non-small cell lung cancer.|
Call for more information